North America Rapid Diagnostics Market 2021-2031 by Product (Consumables, Analyzers/Instruments), Prescription (Professional, OTC), Platform (Immunoassays, Molecular Detection, Others), Application, End User, and Country: Trend Forecast and Growth Opportunity

North America Rapid Diagnostics is projected to grow by 6.5% annually in the forecast period and reach $29,905.4 million by 2031, driven by the growing demand for POC diagnostics, the rising prevalence of chronic diseases coupled with the increasing aging population, the growing necessity for rapid decision making in emergency departments, increase in awareness regarding early diagnosis of disease, and emerging technological innovations.
Highlighted with 28 tables and 61 figures, this 120-page report "North America Rapid Diagnostics Market 2021-2031 by Product (Consumables, Analyzers/Instruments), Prescription (Professional, OTC), Platform (Immunoassays, Molecular Detection, Others), Application, End User, and Country: Trend Forecast and Growth Opportunity" is based on comprehensive research of the entire North America Rapid Diagnostics market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2019-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter's Fiver Forces
The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify North America Rapid Diagnostics market in every aspect of the classification from perspectives of Product, Prescription, Platform, Application, End User, and Country.

Based on Product, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Consumables
• Analyzers/Instruments

Based on Prescription, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Professional Diagnostics
• OTC Based Testing

By Platform, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Immunoassays
o Lateral Flow Assays
o Serological Assays
o Other Immunoassays
• Molecular Detection
o Polymerase Chain Reaction (PCR)
o Other Molecular Detection Tests
• Other Platforms

By Application, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Blood Glucose Testing
• Cardiometabolic Testing
• Infectious Disease Testing
o COVID-19 Testing
o Healthcare-associated Infections (HAI) Testing
o Hepatitis Testing
o Tropical Diseases Testing
o HIV Testing
o Influenza Testing
o Sexually Transmitted Diseases (STD) Testing
o Other Infectious Diseases Testing
• Blood Coagulation Testing
• Hematology Testing
• Cancer Testing
• Drug Abuse Testing
• Pregnancy & Fertility Testing
• Other Applications

By End User, the North America market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
• Hospitals & Clinics
• Laboratories
• Individuals/Homecare
• Other End Users

Geographically, the following national/local markets are fully investigated:
• U.S.
• Canada
• Mexico
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Product, Prescription and Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Abbott Diagnostics
ACON Laboratories
Becton Dickinson and Co.
BioMérieux S.A.
Bio-Rad Laboratories, Inc.
Chembio Diagnostic Systems
Danaher Corp.
F. Hoffmann La Roche Ltd.
GlySens Inc.
Meridian Bioscience Inc.
OraSure Technologies Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Trinity Biotech Plc
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)